At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
dalfampridine-ER 10mg +1 moredrug
Likely dose
dalfampridine-ER 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
In Brief
A Phase 1 clinical trial evaluating dalfampridine-ER 10mg and Placebo for Cerebral Palsy (CP). Completed, enrolled 35 participants across 11 sites.
Detailed Summary
A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Palsy (CP)
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionJan 2013
Study CompletionMar 2013
TodayJul 2026
First PostedNov 9, 2011
Enrollment StartDec 1, 2011
Primary CompletionJan 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.6 years ago
Interventions
dalfampridine-ER 10mgdrug
Placeboother